Page last updated: 2024-09-05

sb 203580 and mebendazole

sb 203580 has been researched along with mebendazole in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(mebendazole)
Trials
(mebendazole)
Recent Studies (post-2010) (mebendazole)
3,48941,1372,089184438

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)mebendazole (IC50)
Tyrosine-protein kinase ABL1Homo sapiens (human)5
Vascular endothelial growth factor receptor 2Homo sapiens (human)5.5667
Calmodulin-domain protein kinase 1Toxoplasma gondii0.67

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fukami, T; Mizuno, K; Nakajima, M; Toyoda, Y; Yokoi, T1

Other Studies

1 other study(ies) available for sb 203580 and mebendazole

ArticleYear
Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway.
    Archives of toxicology, 2011, Volume: 85, Issue:3

    Topics: Anthracenes; Antinematodal Agents; Cell Line, Tumor; Cells, Cultured; Chemokines; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Interleukin-8; Mebendazole; Mitogen-Activated Protein Kinases; Monocytes; Pyridines; Tumor Necrosis Factor-alpha

2011